Crucell Terug naar discussie overzicht

PB - Crucell and DSM intensify collaboration

1. aossa 20 februari 2007 11:57

   auteur info

   • aossa

     Lid sinds: 23 mei 2003

     Laatste bezoek: 31 mrt 2025

   • Aanbevelingen

     Ontvangen: 4053

     Gegeven: 3339

   •    Aantal posts: 17.622

   www.investorvillage.com/smbd.asp?mb=2...
   
   There is this paragraph as well
   
   It will take an average of 15 days to produce yields of 10 grammes per litre, according to DSM Pharma. The strengths of the PER.C6 technology lie in its safety profile, scalability and productivity under serum-free culture conditions.
   
   My question is this;
   It takes an aver of 15 days using PER.C6 to produce 10 grammes per litre, is that faster, on average, or slower than it takes to get 2 grams per litre currently? In other words, is this method not only more productive, but also quicker.
2. aossa 20 februari 2007 12:04

   auteur info

   • aossa

     Lid sinds: 23 mei 2003

     Laatste bezoek: 31 mrt 2025

   • Aanbevelingen

     Ontvangen: 4053

     Gegeven: 3339

   •    Aantal posts: 17.622

   Link artikel in In-PharmaTechnologist.
   
   www.in-pharmatechnologist.com/news/ng...
3. [verwijderd] 21 februari 2007 09:44

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   En nog een; dank aan Trudy.
   
   cancerfocus.net/node/239
4. aossa 21 februari 2007 10:00

   auteur info

   • aossa

     Lid sinds: 23 mei 2003

     Laatste bezoek: 31 mrt 2025

   • Aanbevelingen

     Ontvangen: 4053

     Gegeven: 3339

   •    Aantal posts: 17.622

   quote:

   wpw schreef:

   En nog een; dank aan Trudy.
   
   cancerfocus.net/node/239
   

   PER.C6 Technology from Crucell Could Soon Herald Lowered Costs for Antibody Treatments
   
   Crucell in a partnership with DSM have announced that production of monoclonal antibodies has reached 10g/L (grams per liter) of cell culture, using the PER.C6 platform to produce the yields. Current standard methods yield monoclonal antibodies around 1-2g/L. This order of magnitude increase in yield could help lower the cost for producing the current monoclonal antibodies used in treatments for cancer today. The price of drugs has soared for cancer treatment and the monoclonal antibody is no exception. Herceptin costs around $3,000 a month, Avastinterm is at $4,400, Erbituxterm costs around $10,000 a month, and Rituxanterm can range from $4,200 to $13,000 a month depending on treatment. A great article on recent drug costs can be found here on the USA Today site.
   
   The PER.C6 technology is based on the human retina cells. A human retina cell was transformed and immortalized with adenovirus DNA. This allowed the cell to grow indefinitely. Recombining new DNA into the transformed cell allows the production of proteins encoded in the DNA, including antibodies. The antibodies produced are functional and meet industry standards, since these cells can be grown in controlled media without the presence of serum.
   
   Go CRXL!!!
   
   Trudy the Monkey
   
   messages.finance.yahoo.com/Stocks_%28...
   
   www.investorvillage.com/smbd.asp?mb=2...